Category

Press Release
Predicine presented data highlighting the use of PredicineCARE and PredicineATLAS in patients with metastatic breast cancer and early stage bladder cancer. Publications can be found below: (Breast Cancer Abstract) (Bladder Cancer Abstract)    
Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer. The publications can be found online at: (HERE)
Results from the studies utilizing Predicine’s blood-based liquid biopsy assay to detect copy number loss in PTEN, RB1, TP53, etc. are now published in Frontiers in Oncology and JCO Precision Oncology, respectively. Predicine, Inc. announced today results from two liquid biopsy studies demonstrating the technical capability and clinical application of the PredicineCARE™ liquid biopsy NGS...
Results from the study using liquid biopsy to detect copy number variations (CNVs), especially PTEN copy number loss, are now published in JCO Precision Oncology. Predicine, Inc. today announced results from a prostate cancer liquid biopsy study evaluating the landscape of genomic alterations in 231 patients with metastatic castration-resistant prostate cancer (mCRPC) from US and...
Data presentations to show clinical utility of Predicine’s urine- and blood-based liquid biopsy solutions for precision cancer care and clinical drug development. Predicine announced today that new liquid biopsy data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancer Symposium, taking place from February 11-13, 2021. Among featured highlights are...
Epic’s Comprehensive Cancer Profiling™ now includes the broadest ctDNA assay PredicineATLAS™   Predicine, a molecular insights company headquartered in Hayward, California and Epic Sciences, Inc. today announced they have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing. Predicine’s lead offering is PredicineATLAS™, the...
This unprecedented time is especially troubling for people fighting with cancer. At Predicine, our primary focus remains our commitment to deliver genomic testing to physicians and cancer patients in need. Our global labs in San Francisco and Shanghai remain open and operational with precautionary measures put in place to ensure we are keeping our employees safe as...
Predicine and Merck KGaA, Darmstadt, Germany collaboratively highlight the importance of multi-parametric profiling of ctDNA and cfRNA for holistic molecular insight for detecting driver mutation, monitoring disease burden and drug resistance in advanced stage colorectal cancer. Predicine, a molecular insights company headquartered in Hayward, California, with global footprints in China, today announced results from a...
Predicine today announced a strategic partnership with FMD to help biopharma companies accelerate biomarker-driven clinical trials and concurrent New Drug Application (NDA) submissions in the U.S. and China. The collaboration structure allows for global development of novel oncology therapies for biopharmaceutical companies, including global clinical trial support, regulatory support, and biomarker-driven drug development, and CDx...
Liquid biopsies are being widely studied as a minimally-invasive means for early detection of cancer, monitoring of disease progression, and guiding treatment decisions. However, recent studies in JAMA Oncology reported the discordance between circulating tumor DNA (ctDNA) assay results from commercial platforms such as Guardant Health and PGD, raising questions and concerns regarding the performance...
1 2